Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xbrane And Stada Celebrate Major Milestone With EU Filing For Lucentis Rival

Xlucane Asset Joins Bioeq/Formycon FYB201 Biosimilar With EMA

Executive Summary

Xbrane Biopharma has taken a key step on its journey to begin generating cash from operations by early 2024 at the latest, after its Xlucane biosimilar ranibizumab asset was submitted to the European Medicines Agency by co-development and commercialization partner Stada.

You may also be interested in...



Stada And Xbrane Gain EU All-Clear For Ranibizumab Biosimilar

The European Commission has approved Stada and Xbrane’s Ximluci ranibizumab biosimilar, the third Lucentis rival to be approved in the region so far. The companies are aiming to launch in early 2023 in selected European markets.

AstraZeneca/Sanofi’s RSV Shot Among 13 Hopefuls Awaiting EU Verdict

Its crunch time for sponsors of more than a dozen products as the EMA meets to adopt opinions on several marketing authorization applications.

Xbrane Reveals Ranibizumab Refiling Plans For US

Xbrane has set out its plans to resubmit its application for a biosimilar rival to Lucentis in the US, after receiving details from the FDA on additional information needed for the agency to accept the BLA for review.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel